Disease Modelling & Screening Platform (dmsp)
The disease modelling and screening platform (DMSP) is a core facility that provides infrastructure and services related to early drug discovery.
activities
DMSP is the result of the collaboration between the Luxembourg Centre for Systems Biomedicine at the University of Luxembourg (LCSB/UL) and LIH. The platform combines the cellular disease modelling expertise of both institutions with early drug discovery technology.
The ultimate objective of the DMSP is to provide a diversity of core facilities infrastructure, disease models and expertise, to facilitate the translation of basic scientific discoveries into tangible hit (drug) candidates. Our state-of-the-art platform acts as interface between fundamental biomedical research and high standard drug discovery:
- to help researchers to develop screenings based on their biological findings
- to perform High Throughput Screenings (HTS) for them with our compounds or their own library
- to develop new cellular disease models for phenotypic screening (HCS)
- to offer phenotypic screenings in established patient-derived cellular models
Featured team members
-
Meritxell
Cutrona Head of DMSP -
Arkadiusz
Rybicki Laboratory Technician -
Bruno
Santos Project Leader in Translational Research
Scientific publications
-
Personalized functional profiling using ex-vivo patient-derived spheroids points out the potential of an antiangiogenic treatment in a patient with a metastatic lung atypical carcinoid – 31/12/2022
-
Personalized drug screening for functional tumor profiling – 15/11/2021
-
Patient-Derived Tumor Organoids for Guidance of Personalized Drug Therapies in Recurrent Glioblastoma – 12/06/2022
-
Gene-corrected p.A30P SNCA patient-derived isogenic neurons rescue neuronal branching and function – 09/11/2021
-
Mitochondria interaction networks show altered topological patterns in Parkinson’s disease – 01/12/2020
-
Generation of two iPS cell lines (HIHDNDi001-A and HIHDNDi001-B) from a Parkinson’s disease patient carrying the heterozygous p.A30P mutation in SNCA – 01/10/2020
-
Using High-Content Screening to Generate Single-Cell Gene-Corrected Patient-Derived iPS Clones Reveals Excess Alpha-Synuclein with Familial Parkinson’s Disease Point Mutation A30P – 10/09/2020
-
The envelope cytoplasmic tail of HIV-1 Subtype C contributes to poor replication capacity through low viral infectivity and cell-To-cell transmission – 01/09/2016
-
Isolation of an HIV-1 neutralizing peptide mimicking the CXCR4 and CCR5 surface from the heavy-chain complementary determining region 3 repertoire of a viremic controller – 28/01/2016
-
Erratum – 02/07/2013
